BGLCNasdaqServices-Medical LaboratoriesFiscal year ends December 31
BioNexus Gene Lab Corp
Financials through Q2 FY2026, quarter ended Jun 30, 2026Last filing: 10-Q on Aug 14, 2026
$1.23+0.03 (+2.23%)
Close on Oct 19, 2026
- Market cap
- $2.97M
- P/E (TTM)
- –
- Dividend yield
- –
BioNexus Gene Lab Corp revenue by segment
By business segment
By product or service
By region
| Revenue | FY2025 | FY2024 | FY2023 | % of revenue | YoY |
|---|---|---|---|---|---|
| Myanmar | $5.83M | $7.46M | – | 78.5% | -21.8% |
| Maldives | $680.99K | $762.14K | $637.19K | 9.2% | -10.6% |
| Sri Lanka | $452.64K | $459.00K | $87.03K | 6.1% | -1.4% |
| Singapore | $240.76K | $572.03K | $244.40K | 3.2% | -57.9% |
| INDONESIA | $114.87K | $138.30K | $0 | 1.5% | -16.9% |
| Bangladesh | $106.25K | $123.27K | $538.06K | 1.4% | -13.8% |
| Malaysia | – | $7.46M | $8.22M | – | – |
| Nigeria | – | $0 | $42.07K | – | – |
From the segment and revenue-disaggregation notes of BioNexus Gene Lab's 10-K and 10-Q filings (XBRL). Fourth-quarter figures are the fiscal year less the first nine months. Segment names follow the company's own labels and can change when it reorganizes.